Introduction {#tca12577-sec-0005}
============

The era of molecular‐targeted therapy for non‐small cell lung cancer (NSCLC) is emerging. Previously, platinum‐based doublet chemotherapy was the standard of care, but resulted in poor prognosis with median overall survival (OS) of 8--10 months and a one‐year survival rate of 30--35%.[1](#tca12577-bib-0001){ref-type="ref"} The adoption of *EGFR*‐ tyrosine kinase inhibitors TKIs, such as erlotinib and gefitinib, has changed the potential outcome for *EGFR* mutation‐positive metastatic NSCLC patients dramatically.[2](#tca12577-bib-0002){ref-type="ref"}, [3](#tca12577-bib-0003){ref-type="ref"}, [4](#tca12577-bib-0004){ref-type="ref"}, [5](#tca12577-bib-0005){ref-type="ref"}, [6](#tca12577-bib-0006){ref-type="ref"}, [7](#tca12577-bib-0007){ref-type="ref"}, [8](#tca12577-bib-0008){ref-type="ref"} A series of studies have focused on comparing TKIs to chemotherapy. The IPASS study found that chemotherapy and gefitinib could significantly improve efficiency (response rate, RR) and progression‐free survival (PFS), particularly in patients with specific characteristics (i.e. Asian, female, non‐smoker) for whom gefitinib showed superiority over chemotherapy.[4](#tca12577-bib-0004){ref-type="ref"} Other phase III studies have achieved similar results.[9](#tca12577-bib-0009){ref-type="ref"}, [10](#tca12577-bib-0010){ref-type="ref"}, [11](#tca12577-bib-0011){ref-type="ref"} The TORCH study, which included patients with no specific molecular biology requirements, showed that chemotherapy as first‐line and erlotinib as second‐line treatment confers better survival rates than erlotinib as first‐line and chemotherapy as second‐line treatment.[12](#tca12577-bib-0012){ref-type="ref"} However, the optimal treatment regimen has not yet been discovered. We conducted this retrospective study to determine the kinds of treatments that NSCLC patients in China receive in real world clinical practice that might contribute to improved OS in patients treated with *EGFR*‐TKIs. With the current aging of the world\'s population and the popularity of physical examinations, an increasing number of elderly patients are being diagnosed. Very few studies have been specifically designed to definitively identify whether TKIs should be administered to elderly patients.[13](#tca12577-bib-0013){ref-type="ref"} Thus, this study also sheds light on whether elderly patients may benefit from TKI treatment.

Methods {#tca12577-sec-0006}
=======

Patients {#tca12577-sec-0007}
--------

Patients with previous histologic or cytologic confirmation of local; advanced stage (IIIA or IIIB) or stage IV; or recurrent, metastatic NSCLC were eligible for the study. The patients were required to be aged ≥18, with at least one measurable focus fitting the Response Evaluation Criteria in Solid Tumors, and had been diagnosed using computed tomography or nuclear magnetic resonance imaging. Neoplasms at unique foci must have been histologically or cytologically confirmed. This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of Anhui Chest Hospital. Written informed consent was obtained from all participants.

Toxicity evaluation {#tca12577-sec-0008}
-------------------

Drug‐induced toxicity was classified in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.

Related medical definition of the concept {#tca12577-sec-0009}
-----------------------------------------

Median survival time (MST) is the time by which death occurs in 50% of cases. OS refers to the duration from initial treatment to death from any cause.

Statistical analysis {#tca12577-sec-0010}
--------------------

EpiData bidirectional verification was used for data entry (EpiData Association, Odense, Denmark). A Chi square test was used to compare differences based on stratification: gender, performance status, age, histology, *EGFR* status, staging, and prior chemotherapy regimens. Median OS was calculated using the Kaplan--Meier method and differences between the levels of possible prognostic factors were compared using the log rank test in univariate analyses. Multivariate analysis with covariate adjusted Cox regression was then performed to identify prognostic factors. A value of *P* \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

Results {#tca12577-sec-0011}
=======

Baseline characteristics {#tca12577-sec-0012}
------------------------

Data of 463 patients (212 men, 251 women) was collected from 16 hospitals. Patient age ranged from 22 to 93, with a median of 62 years. Pathological types included adenocarcinoma (340 cases), squamous cell carcinoma (48 cases), large cell carcinoma (4 cases), undifferentiated (35 cases), and other (36 cases). *EGFR* was detected in 130 cases (28.1%), of which 11 harbored wild type and 119 harbored *EGFR* mutations. The classified stages were distributed as follows: IIIa, 9 cases; IIIb, 48 cases; IVa, 152 cases; and IVb, 243 cases.

Tyrosine kinase inhibitors were administered as first‐line treatment in 172 cases (37.1%), as second‐line in 220 (47.5%), and as third‐line in 67 (14.4%). Four patients received TKIs beyond third‐line treatment, four patients received both gefitinib and icotinib as second‐line treatment, and three patients received both gefitinib and erlotinib as third‐line treatment. A comparison of the baseline characteristics of patients according to the timing of *EGFR*‐TKI treatment is summarized in Table [1](#tca12577-tbl-0001){ref-type="table-wrap"}.

###### 

Baseline characteristics of the three groups

  Characteristic         First‐line    Second‐line     Third‐line
  -------------------- -------------- -------------- --------------
  Age                                                
  \< 65                      74            149             41
  ≥ 65                       96             71             26
  Gender                                             
  Male                       71             94             44
  Female                     99            126             23
  Adenocarcinoma                                     
  116                       181             41       
  Non‐adenocarcinoma                                 
  54                         39             26       
  Stage                                              
  IIIa                       5              2              2
  IIIb                       18             24             4
  IVa                        75             65             12
  IVb                        70            124             49
  KPS                   70 (30--100)   70 (30--100)   70 (10--100)

KPS, Karnofsky performance status.

The 220 patients in the second‐line treatment group tended to be younger than those who received *EGFR*‐TKIs as first‐line or third‐line therapy (\<65 years 67.7% vs. 43.5% and 61.2%, respectively; *P* = 0.000), women (42.7% vs. 41.8% and 65.7%, respectively; *P* = 0.000), and with adenocarcinoma (81.8% vs. 68.2% and 61.2%, respectively; *P* = 0.001). There was no significant difference in stage or Karnofsky performance score (KPS) between the three groups.

Survival analysis {#tca12577-sec-0013}
-----------------

The median OS in the first‐line treatment group was 15 months (95% confidence interval \[CI\] 12.3--17.6), in the second‐line group 16 months (95% CI 13.7--18.2), and in the third‐line group 16 months (95% CI 5.4--26.6); these results were relatively insignificant (*P* = 0.146) (Fig [1](#tca12577-fig-0001){ref-type="fig"}a).

![Overall survival comparison of: (**a**) the three groups, (**b**) elderly, (**c**) *EGFR*‐mutation positive, and (**d**) the three *EGFR*‐mutation positive groups of patients. Blue, first‐line; green, second‐line; yellow, third‐line; blue line with dash, first‐line censored; green line with dash, second‐line censored; yellow line with dash, third‐line censored.](TCA-9-278-g001){#tca12577-fig-0001}

The one, two, and three‐year survival rates were: 55.3%, 22.3%, and 11.3% in the first‐line treatment group; 59.6%, 27.8%, and 14.9% in the second‐line; and 53.8%, 41.3%, and 29.5% in the third‐line treatment group, respectively. The survival rates between the three groups were relatively insignificant (*P* = 0.095).

Survival analysis of elderly patients {#tca12577-sec-0014}
-------------------------------------

A total of 194 patients were aged \>65 years. Ninety‐seven patients received TKIs as first‐line treatment. The MST was 13 months (95% CI 9.9--16.1), and the one, two, and three‐year survival rates were 53.1%, 22.4%, and 13.4%, respectively. Seventy‐one patients received TKIs as second‐line treatment. The MST was 13 months (95% CI 10.1--15.9), and the one, two, and three‐year survival rates were 56.3%, 21.3%, and 10.1%, respectively. Twenty‐six patients received TKIs as third‐line treatment. The MST was 13 months (95% CI 7.4--18.6), and the one, two, and three‐year survival rates were 52.3%, 39.2%, and 25.4%, respectively. The survival differences between the three groups of patients were relatively insignificant (*P* = 0.469) (Fig [1](#tca12577-fig-0001){ref-type="fig"}b).

Survival analysis of *EGFR* mutation‐positive patients {#tca12577-sec-0015}
------------------------------------------------------

Comparisons of the baseline characteristics of *EGFR* mutation‐positive patients according to the timing of *EGFR*‐TKI treatment are summarized in Table [2](#tca12577-tbl-0002){ref-type="table-wrap"}.

###### 

Baseline characteristics of *EGFR* mutation‐positive patients

  Characteristic         First‐line    Second‐line   Third‐line
  -------------------- -------------- ------------- -------------
  Age                                               
  \< 65                      28             9             3
  ≥ 65                       29            40            10
  Gender                                            
  Male                       22            25             7
  Female                     35            24             6
  Adenocarcinoma                                    
  46                         42             8       
  Non‐adenocarcinoma                                
  11                         7              5       
  Stage                                             
  IIIa                       2              0             1
  IIIb                       5             10             0
  IVa                        45             9             2
  IVb                        15            30            10
  KPS                   60 (30--100)   70 (50--90)   70 (30--80)

KPS, Karnofsky performance status.

*EGFR* mutation‐positive patients who received *EGFR*‐TKIs as first‐line treatment were younger than those who received *EGFR*‐TKIs as second‐line treatment (\<65 years, 49% vs. 18.4%; *P* = 0.001). The KPS was higher in the second‐line than in the third‐line treatment group (*P* = 0.03). There were no significant differences in gender, pathology, or stage between the three groups.

The one, two, and three‐year OS rates of *EGFR* mutation‐positive patients were 53.4%, 28.2%, and 21.1%, respectively (Fig [1](#tca12577-fig-0001){ref-type="fig"}c).

Fifty‐seven *EGFR* mutation‐positive patients received TKIs as first‐line therapy. The one and two‐year survival rates were 48% and 17.5%, respectively. Forty‐nine patients received second‐line treatment and the one, two, and three‐year survival rates were 54.2%, 30.3%, and 20.2%, respectively. Thirteen patients received third‐line TKIs. The one and two‐year survival rates were 69.8% and 58.2%, respectively, which were higher than in the other two groups (*P* = 0.015) (Fig [1](#tca12577-fig-0001){ref-type="fig"}d).

Prognostic factors {#tca12577-sec-0016}
------------------

Clinical variables associated with the OS of all patients were analyzed (Table [3](#tca12577-tbl-0003){ref-type="table-wrap"}). Higher KPS correlated with improved OS (*P* = 0.059).

###### 

Prognostic factors for overall survival

  Factors                        N (%)   MST (months)   95% CI (months)   x^2^     *P*
  ----------------------------- ------- -------------- ----------------- ------- -------
  All                             463         15        13.106--16.894           
  Gender                                                                         
  Male                            212         11         8.798--13.202    2.673   0.102
  Female                          251         17        15.219--18.781           
  Age                                                                            
  \< 65                           263         17        13.786--20.214    0.406   0.524
  ≥ 65                            198         13        10.323--15.677           
  Histology                                                                      
  Adenocarcinoma                  340         16        13.782--18.218    1.147   0.284
  Non‐adenocarcinoma              113         11         8.443--13.557           
  KPS                                                                            
  \< 70                           174         14        11.417--16.583    3.564   0.059
  ≥ 70                            257         17        13.475--20.525           
  Metastasis before treatment                                                    
  Yes                             281         16        13.161--18.839    0.12    0.729
  No                              156         14        11.120--16.880           
  Disease progress                                                               
  Pulmonary                       136         12         9.765--14.235    0.149    0.7
  Extra‐pulmonary                 221         16        13.226--18.774           

CI, confidence interval; KPS, Karnofsky performance status; MST, median survival time.

Discussion {#tca12577-sec-0017}
==========

In the last 10 years, the advent of targeted drugs has offered new treatment options for patients with NSCLC. *EGFR* is an important mature research target as it can activate multiple downstream signaling pathways, such as the Ras‐Raf‐MAPK, JAK‐STAT, and P13K‐Akt pathways, which contribute to cell signaling, promotion of cell proliferation, metastasis, and inhibition of apoptosis. *EGFR*‐TKIs, by binding to the *EGFR* adenosine triphosphate (ATP)‐competitive inhibitory site of the *EGFR* intracellular tyrosine kinase moiety, directly reduce the autophosphorylation of *EGFR*, leading to cell growth arrest and the promotion of apoptosis.[14](#tca12577-bib-0014){ref-type="ref"}

This multi‐center study involved retrospective analysis. All patients were diagnosed with advanced NSCLC, 73.4% of which were adenocarcinomas. The detection rate of *EGFR* gene mutations was 28.1%.

In our study, the majority (47.5%) of patients received TKIs as second‐line treatment. Their one, two, and three‐year survival rates (59.6%, 27.8%, and 14.9%, respectively) were slightly higher than those of the first‐line treatment group (55.3%, 22.3%, and 11.3%, respectively). This may be explained by the fact that patients receiving second‐line treatment were younger, women, and had adenocarcinomas. However, this finding was statistically insignificant.

In this study, 47.9% of elderly patients received TKIs as first‐line treatment. The IPASS study found that the *EGFR* mutation‐positive rate was 68.5% in patients aged \>65 and 56.7% in patients aged \<65.[4](#tca12577-bib-0004){ref-type="ref"} The *EGFR* mutation rates in elderly patients with advantageous characteristics (i.e. Asian, female, non‐smoker) may be even higher. The TORCH study found that after first‐line chemotherapy, 28.5% patients died as a result of deteriorating health conditions that prevented them from receiving erlotinib as second‐line treatment.[12](#tca12577-bib-0012){ref-type="ref"} A study in Korea showed that the efficacy rate of octogenarians receiving first‐line TKI therapy was 80%, and the median OS of patients receiving TKIs was 24.1 months.[15](#tca12577-bib-0015){ref-type="ref"} *EGFR*‐TKI therapy is more suitable for older patients because of its lower cytotoxicity, allowing patients to lead a better quality of life.[16](#tca12577-bib-0016){ref-type="ref"}, [17](#tca12577-bib-0017){ref-type="ref"}

Some phase III studies involving patients with *EGFR*‐positive NSCLC did not demonstrate improved OS, despite an improvement in PFS with first‐line *EGFR*‐TKI therapy.[12](#tca12577-bib-0012){ref-type="ref"} According to our analysis, the OS of *EGFR* mutation‐positive patients was not superior to other patients, and there were no significant survival differences between the patients that received first‐line *EGFR*‐TKI therapy and those that underwent one or two courses of prior chemotherapy. This finding is similar to the results demonstrated by previous Asian studies.[18](#tca12577-bib-0018){ref-type="ref"}, [19](#tca12577-bib-0019){ref-type="ref"}, [20](#tca12577-bib-0020){ref-type="ref"} Survival rates in the third‐line treatment group were higher than those in the other two groups because there were only 13 patients in this group.

This study demonstrates that TKIs confer survival benefits to patients; however no statistically significant survival difference was observed between different treatment timings.
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